Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Receivables - Other (2016 - 2020)

Historic Receivables - Other for Ironwood Pharmaceuticals (IRWD) over the last 12 years, with Q1 2020 value amounting to $73.4 million.

  • Ironwood Pharmaceuticals' Receivables - Other rose 588.24% to $73.4 million in Q1 2020 from the same period last year, while for Mar 2020 it was $73.4 million, marking a year-over-year increase of 588.24%. This contributed to the annual value of $106.0 million for FY2019, which is 7673.24% up from last year.
  • Ironwood Pharmaceuticals' Receivables - Other amounted to $73.4 million in Q1 2020, which was up 588.24% from $106.0 million recorded in Q4 2019.
  • Ironwood Pharmaceuticals' Receivables - Other's 5-year high stood at $106.0 million during Q4 2019, with a 5-year trough of $50.0 million in Q1 2017.
  • Its 5-year average for Receivables - Other is $68.3 million, with a median of $65.7 million in 2018.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Receivables - Other soared by 9958.06% in 2016 and then tumbled by 2720.34% in 2018.
  • Over the past 5 years, Ironwood Pharmaceuticals' Receivables - Other (Quarter) stood at $63.9 million in 2016, then increased by 23.54% to $79.0 million in 2017, then decreased by 24.07% to $60.0 million in 2018, then soared by 76.73% to $106.0 million in 2019, then plummeted by 30.73% to $73.4 million in 2020.
  • Its last three reported values are $73.4 million in Q1 2020, $106.0 million for Q4 2019, and $94.6 million during Q3 2019.